AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis
Emicizumab is well tolerated and appears to maintain or improve joint health in pediatric PwHA.
Authors
- Daisuke Nosaka
- Keiji Nogami (ORCID: https://orcid.org/0000-0002-2415-2194)
- Akira Ishiguro (ORCID: https://orcid.org/0000-0002-3896-5313)
- Midori Shima (ORCID: https://orcid.org/0000-0002-5922-7061)
- Chiai Nagae
- Kaoru Kitsukawa (ORCID: https://orcid.org/0000-0003-0559-8366)
- Azusa Nagao (ORCID: https://orcid.org/0000-0002-1126-1498)
- Hideyuki Takedani (ORCID: https://orcid.org/0000-0001-7707-4778)
- Yui Kyogoku
- Keisuke Iwasaki
- Hiroki Oki
- Masashi Taki
Institutions
- Chiba University (JP)
- St. Marianna University School of Medicine (JP)
- Municipal Tsuruga Hospital (JP)
- Ogikubo Hospital (JP)
- Chugai Pharma (United States) (US)
- National Center For Child Health and Development (JP)
- National Hospital Organization (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1016/j.rpth.2025.103228
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Bayer
- Sanofi
- CSL Behring
- Novo Nordisk
- Chugai Pharmaceutical